Photodynamic performance and anti-lung cancer effect of novel chlorin compounds
10.12206/j.issn.2097-2024.202304011
- VernacularTitle:新型二氢卟吩化合物的光动力性能及其抗肺癌作用研究
- Author:
Yan QIU
1
;
Hao WU
1
;
Yafen DONG
1
;
Ye CHEN
1
;
Jian WANG
1
;
Hui JIN
1
Author Information
1. Department of Pharmacy, b. Department of Hospital Infection, Shanghai Pudong New Area People’s Hospital, Shanghai 201299, China.
- Publication Type:Originalarticles
- Keywords:
lung cancer;
chlorin;
photodynamic therapy;
pharmacological evaluation
- From:
Journal of Pharmaceutical Practice and Service
2026;44(1):39-45
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the photodynamic performance and the killing effect of photodynamic therapy on lung cancer of novel chlorin compounds 2-（4-（5,15,20-triphenyl-7H,8H-porphyrin-10-yl） phenoxy） acetic acid（D1）and 4-（4-（5,15,20-triphenyl-7H,8H-porphyrin-10-yl） phenoxy） butanoic acid （D2）. Methods The ultraviolet visible absorption spectrum and fluorescence spectrum of D1 and D2 were determined. The singlet oxygen generation capacity of D1 and D2 was measured by using DPBF as singlet oxygen capture agent. Fluorescence assay was used to detect the cellular phagocytosis rate of the compounds in A549 cells, and MTT assay was used to detect their dark toxicity and phototoxicity. A nude mouse model of lung cancer was established to investigate the antitumor activity of the compounds mediated photodynamic action in vivo, and the blood concentration of D2 in nude mice, its distribution in tumor tissue and skin tissue were further detected. Results D1 and D2 had strong absorption at 652 nm with the best excitation wavelength at 429 nm and 427 nm, and the optimal emission wavelength was at about 659 nm. They also had a higher singlet oxygen generation rate than the control drug m-THPC. D1 and D2 had no dark toxicity at concentrations below 10 μmol/L, and could be ingested by A549 cells, basically reaching saturation in 18~24 hours. After laser irradiation at 650 nm wavelength, D1 and D2 showed significant antitumor activity in vivo and in vitro （P<0.01）. However, D2 could selectively accumulate in tumor tissues after administration, and the optimal treatment time was less than 30 min after administration. Conclusion D2 had excellent photodynamic antitumor activity and could selectively aggregate in tumor tissues, which had the potential to be a candidate drug for photosensitizer and treatment of lung cancer with independent intellectual property rights, and was worth further research.
